Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].

Literature DB >> 31853892

[Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].

Martin Boegemann¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2020 PMID： 31853892 DOI： 10.1007/s00120-019-01096-6

Source DB: PubMed Journal: Urologe A ISSN： 0340-2592 Impact factor: 0.639

Keyword Cloud
References

× No keyword cloud information.

2 in total

1. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Authors: Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury
Journal: N Engl J Med Date: 2019-05-31 Impact factor: 91.245

2. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Authors: Andrew J Armstrong; Russell Z Szmulewitz; Daniel P Petrylak; Jeffrey Holzbeierlein; Arnauld Villers; Arun Azad; Antonio Alcaraz; Boris Alekseev; Taro Iguchi; Neal D Shore; Brad Rosbrook; Jennifer Sugg; Benoit Baron; Lucy Chen; Arnulf Stenzl
Journal: J Clin Oncol Date: 2019-07-22 Impact factor: 44.544

2 in total